Biosecure revised, and venture rounds, deals of note: a BioCentury podcast

What’s new in legislation seeking to rein in influence of China’s CDMOs

Lawmakers’ changes to the Biosecure Act create breathing room for U.S. biopharma companies to move on from Chinese CDMOs, Washington Editor Steve Usdin said. On the latest BioCentury This Week podcast, Usdin and his BioCentury colleagues discuss what the revisions mean for biotechs and what’s next for the legislation, plus how WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) is defending itself against the bill’s allegations.

Director of Biopharma Intelligence Paul Bonanos discusses last week’s surge in venture activity, including the largest biotech round, a $200 million series C by Lonnie Moulder’s Zenas BioPharma Inc., as well as recent deals of note, including one for  Maze Therapeutics Inc. The biotech found a new partner for its Pompe disease program in Shionogi & Co. Ltd. (Tokyo:4507), months after Sanofi (Euronext:SAN; NASDAQ:SNY) pulled out of a deal for the therapy amid Federal Trade Commission scrutiny.

This episode of BioCentury This Week was sponsored by Nxera Pharma Co. Ltd. For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.